PFE — PFIZER INC catalysts

Name: Bio Catalyst Calendar — source-anchored biotech/pharma catalyst dates
Creator: Bio Catalyst Calendar
License: https://www.usa.gov/government-works

16 verified catalyst event(s) for PFIZER INC (ticker PFE). Each is linked to its official source. Verified as of 2026-09-20.

Next verified catalyst

2026-09-23 — Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Soli · official source ↗

Upcoming

Date	Event	Company	Drug	Official source & verification
2026-09-23 in 3d ESTIMATED	READOUT Study to Test the Safety and Tolerability of PF-07220060 in Participants With Ad Phase 2 · Liposarcoma, Prostate Cancer	PFE PFIZER INC	PF-07220060, Letrozole, Fulvestrant, Mid	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-19 in 29d ESTIMATED	READOUT A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In Peop Phase 2 · Atopic Dermatitis	PFE PFIZER INC	PF-07275315, PF-07264660	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-10-30 in 1mo ESTIMATED	READOUT A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrol Phase 3 · Melanoma	PFE PFIZER INC	Encorafenib, Binimetinib, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-11-29 in 2mo ESTIMATED	READOUT A Study to Learn About the Study Medicine Called Rimegepant in Women When Used f Phase 3 · Menstrual Migraine	PFE PFIZER INC	Rimegepant, Rimegepant	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-02 in 2mo ESTIMATED	READOUT A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Ca Phase 3 · Metastatic Castration-Resistant Prostate Cancer	PFE PFIZER INC	PF-06821497, Enzalutamide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-02 in 2mo ESTIMATED	READOUT A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 t Phase 3 · Severe Alopecia Areata	PFE PFIZER INC	Ritlecitinib higher dose, Ritlecitinib l	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-04 in 3mo ESTIMATED	READOUT A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth D Phase 3 · Lyme Disease	PFE PFIZER INC	VLA15	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-08 in 3mo ESTIMATED	READOUT A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults Phase 2 · Hidradenitis Suppurativa	PFE PFIZER INC	Ritlecitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-25 in 3mo ESTIMATED	READOUT A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spont Phase 2 · Chronic Spontaneous Urticaria	PFE PFIZER INC	Ritlecitinib 50 mg, Ritlecitinib 100 mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-28 in 3mo ESTIMATED	READOUT Lorlatinib Continuation Study Phase 4 · Non-Small-Cell Lung Cancer, NSCLC	PFE PFIZER INC	Lorlatinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-28 in 3mo ESTIMATED	READOUT A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevromet Phase 3 · Metastatic Castrate Resistant Prostate Cancer (mCRPC)	PFE PFIZER INC	PF-06821497, Docetaxel, Enzalutamide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given Phase 1/2 · Breast Cancer	PFE PFIZER INC	ARV-471, Ribociclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-30 in 3mo ESTIMATED	READOUT Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in Phase 3 · Breast Cancer	PFE PFIZER INC	Vepdegestrant (ARV-471/PF-07850327), Pal	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT PF-07104091 as a Single Agent and in Combination Therapy Phase 2 · Small Cell Lung Cancer, Ovarian Cancer	PFE PFIZER INC	PF-07104091 monotherapy dose escalation,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Ave Phase 3 · Advanced Malignancies, NSCLC	PFE PFIZER INC	Avelumab, Lorlatanib, Talazoparib, Pemet	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change
2026-12-31 in 3mo ESTIMATED	READOUT TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given Phase 1/2 · Breast Cancer	PFE PFIZER INC	vepdegestrant, Samuraciclib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-09-20 Sponsor-projected date — can change